The Due Ong

The Due Ong

Auto-generated profile, based on publicly available information

The Due Ong

Department of Health Financing and Health Technology Assessment, Health Strategy and Policy Institute, Ministry of Health, Hanoi, Vietnam

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2019 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Open access
AGAnne Julienne Genuino
Anne Julienne Genuino
UCUsa Chaikledkaew
Usa Chaikledkaew
DTDue Ong The
Due Ong The
TRThanyanan Reungwetwattana
Thanyanan Reungwetwattana
ATAmmarin Thakkinstian
Ammarin Thakkinstian
Objective: Breast cancer remains to be the globally leading female cancer. About 15% to 20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive tumors – a more aggressive breast cancer subtype with shortened survival. In the light of new and updated trial data on trastuzumab therapy for HER2-positive early-stage breast cancer (EBC), we conducted a systematic review and meta-analysis to update the pooling of its relative treatment effects. Methods: Systematic search was performed through Pubmed and Scopus to identify studies comparing survival outcomes and risks of heart toxicity effects of adjuvant trastuzumab with chemotherapy versus chemotherapy alone for HER2-positive EBC patients. Results: Based on the eight included studies in the review, combining trastuzumab with chemotherapy continues to show lowered death and relapse risks by one-third. The decision to initiate trastuzumab, however, needs to be prudently deliberated as two to three times more cardiotoxicity risk was shown to be associated with its use. Conclusion: Administering adjuvant trastuzumab in a weekly cycle concurrently with anthracycline-taxane chemotherapy regimen appears to be a preferable option to optimize its favorable effect in improving DFS and to prevent significantly higher risk for cardiotoxic effects.

7 November 2022 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
CFChuan De Foo
Chuan De Foo
MVMonica Verma
Monica Verma
STSee Mieng Tan
See Mieng Tan
VHVictoria Haldane
Victoria Haldane
KRKatherine Ann Reyes
Katherine Ann Reyes
HLHelena Legido-Quigley
Helena Legido-Quigley
The COVID-19 pandemic will not be the last of its kind. As the world charts a way towards an equitable and resilient recovery, Public Health and Social Measures (PHSMs) that were implemented since the beginning of the pandemic need to be made a permanent feature of health systems that can be activated and readily deployed to tackle sudden surges in infections going forward. Although PHSMs aim to blunt the spread of the virus, and in turn protect lives and preserve health system capacity, there are also unintended consequences attributed to them. Importantly, the interactions between PHSMs and their accompanying key indicators that influence the strength and duration of PHSMs are elements that require in-depth exploration. This research employs case studies from six Asian countries, namely Indonesia, Singapore, South Korea, Thailand, the Philippines and Vietnam, to paint a comprehensive picture of PHSMs that protect the lives and livelihoods of populations. Nine typologies of PHSMs that emerged are as follows: (1) physical distancing, (2) border controls, (3) personal protective equipment requirements, (4) transmission monitoring, (5) surge health infrastructure capacity, (6) surge medical supplies, (7) surge human resources, (8) vaccine availability and roll-out and (9) social and economic support measures. The key indicators that influence the strength and duration of PHSMs are as follows: (1) size of community transmission, (2) number of severe cases and mortality, (3) health system capacity, (4) vaccine coverage, (5) fiscal space and (6) technology. Interactions between PHSMs can be synergistic or inhibiting, depending on various contextual factors. Fundamentally, PHSMs do not operate in silos, and a suite of PHSMs that are complementary is required to ensure that lives and livelihoods are safeguarded with an equity lens. For that to be achieved, strong governance structures and community engagement are also required at all levels of the health system.

9 November 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
TNThi-Phuong-Lan Nguyen
Thi-Phuong-Lan Nguyen
MRM. Rifqi Rokhman
M. Rifqi Rokhman
ISImre Stiensma
Imre Stiensma
RHRachmadianti Sukma Hanifa
Rachmadianti Sukma Hanifa
TOThe Due Ong
The Due Ong
JSJurjen van der Schans
Jurjen van der Schans
Background: Cost-effectiveness analyses (CEAs) on prevention of non-communicable diseases (NCDs) are necessary to guide decision makers to allocate scarce healthcare resource, especially in Southeast Asia (SEA), where many low- and middle-income countries (LMICs) are in the process of scaling-up preventive interventions. This scoping review aims to summarize the cost-effectiveness evidence of primary, secondary, or tertiary prevention of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) as well as of major NCDs risk factors in SEA.Methods: A scoping review was done following the PRISMA checklist for Scoping Reviews. Systematic searches were performed on Cochrane Library, EconLit, PubMed, and Web of Science to identify CEAs which focused on primary, secondary, or tertiary prevention of T2DM, CVDs and major NCDs risk factors with the focus on primary health-care facilities and clinics and conducted in SEA LMICs. Risks of bias of included studies was assessed using the Consensus of Health Economic Criteria list.Results: This study included 42 CEAs. The interventions ranged from screening and targeting specific groups for T2DM and CVDs to smoking cessation programs, discouragement of smoking or unhealthy diet through taxation, or health education. Most CEAs were model-based and compared to a do-nothing scenario. In CEAs related to tobacco use prevention, the cost-effectiveness of tax increase was confirmed in all related CEAs. Unhealthy diet prevention, mass media campaigns, salt-reduction strategies, and tax increases on sugar-sweetened beverages were shown to be cost-effective in several settings. CVD prevention and treatment of hypertension were found to be the most cost-effective interventions. Regarding T2DM prevention, all assessed screening strategies were cost-effective or even cost-saving, and a few strategies to prevent T2DM complications were found to be cost-effective in certain settings.Conclusion: This review shows that the cost-effectiveness of preventive strategies in SEA against T2DM, CVDs, and their major NCDs risk factors are heterogenous in both methodology as well as outcome. This review combined with the WHO “best buys” could guide LMICs in SEA in possible interventions to be considered for implementation and upscaling. However, updated and country-specific information is needed to further assess the prioritization of the different healthcare interventions.Systematic review registration: https://osf.io, identifier: 10.17605/OSF.IO/NPEHT.

11 November 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ODOng The Due
Ong The Due
UCUsa Chaikledkaew
Usa Chaikledkaew
AGAnne Julienne M. Genuino
Anne Julienne M. Genuino
ASAbhasnee Sobhonslidsuk
Abhasnee Sobhonslidsuk
ATAmmarin Thakkinstian
Ammarin Thakkinstian
Direct-acting antivirals (DAAs) are modern treatments for chronic hepatitis C infection, but majority of available evidence on its treatment effect covers genotypes 1 to 4. Therefore, the efficacy and safety of DAAs for genotypes 5 and 6 need to be analysed. Studies were identified from Medline, Scopus, and CENTRAL and a Chinese database CNKI, from inception until Dec 4, 2018. Clinical trials were included if they enrolled patients with genotypes 5 and/or 6 infection, any type of second-generation DAAs was studied, and sustained virological response was assessed at the 12th week after treatment (SVR12) as outcome measure. Meta-analysis using metaprop statistical program was applied for pooling proportions if data were sufficient (i.e., at least 2 studies). Thirteen studies were included in the analysis. Four studies assessed the efficacy of four DAA regimens in genotype 5 patients, which were mainly sofosbuvir (SOF) plus pegylated-interferon/ribavirin (PR) or other DAAs, with SVR12 ranging from 94.4% to 100%. Twelve studies assessed the efficacy of seven DAA regimens among genotype 6 patients, but only two DAA regimens (i.e., SOF + PR and SOF/ledipasvir) had sufficient data for pooling. The pooled SVR12 rates (95% CI) were 99.6% (92.2 to 100) for SOF + PR and 99.2% (96.5 to 100) for SOF/ledipasvir. No treatment-related serious adverse event was reported, while the nonserious adverse events were comparable to other genotypes. In conclusion, DAAs are effective and may be safe for the treatment of chronic hepatitis C genotypes 5 and 6. However, our evidence is based on noncomparative studies; hence, further larger-scale randomized controlled trials in these genotypes are still required.

31 July 2024 in Journal of Preventive Medicine and Public Health
Verified
Journal Article
Open access
PDF file
BTBinh Thang Tran
Binh Thang Tran
GNGia Thanh Nguyen
Gia Thanh Nguyen
DLDinh Duong Le
Dinh Duong Le
NNNhan P. T. Nguyen
Nhan P. T. Nguyen
MNMinh Hanh Nguyen
Minh Hanh Nguyen
TOThe Due Ong
The Due Ong
Objectives: This study was conducted to measure financial toxicity (FT) among patients with cancer in Vietnam using the COmprehensive Score for financial Toxicity (COST) and to describe the cost management strategies employed by these patients.Methods: This comprehensive cross-sectional study enrolled 634 patients from 2 specialized oncology hospitals in Vietnam. Using COST cut-off scores, FT was classified as none/mild (≥26), moderate (14-25), or severe (≤13). Cost management strategies, or coping mechanisms, were classified into 4 groups: lifestyle changes, financial resource strategies, treatment modifications, and support seeking.Results: The prevalence of FT was 91.8%, with 51.7% of participants demonstrating severe and 40.1% exhibiting moderate FT. Severe FT was significantly associated with female, low education level, unstable employment, low household economic status, and advanced cancer stage. The most common coping strategies were as follows: among lifestyle changes, reducing spending on basic items and leisure activities (78.7%) and cutting back on essential household expenses (66.4%); among financial resource strategies, borrowing money from relatives or friends (49.1%) and withdrawing funds from retirement or savings accounts (34.1%); within treatment modifications, switching treatment facilities or doctors due to cost concerns (9.3%); and within support seeking, obtaining help from welfare or community organizations (18.8%). All strategies were significantly more likely to be used by patients with severe FT.Conclusions: FT was highly prevalent among patients with cancer. Most patients relied on lifestyle adjustments and coping strategies, underscoring the need for improved financial support systems to alleviate the economic burden associated with cancer care.

11 September 2026 in Pharmacia
Verified
Journal Article
Open access
PDF file
TOThe Due Ong
The Due Ong
VTVinh-Quang Tran
Vinh-Quang Tran
PNPhung Ngoc Minh Nguyen
Phung Ngoc Minh Nguyen
HNHieu Minh Nguyen
Hieu Minh Nguyen
NPNhat Manh Phan
Nhat Manh Phan
TVTrung Quang VO
Trung Quang VO
Peptic ulcer disease (PUD) imposes a substantial economic burden due to prolonged hospitalization and severe complications. This study evaluated the direct medical costs of inpatient PUD treatment from the healthcare provider perspective in Vietnam. A retrospective study was conducted using the electronic medical records of 1,985 inpatients diagnosed with PUD at a military hospital between 2017 and 2022. Direct medical costs during hospitalization were analyzed using Microsoft Excel 2019 and SPSS version 26.0. The total inpatient treatment cost for PUD during the study period was USD 4,142,121, with a mean cost of USD 2,086.7 per patient. Medication costs amounted to USD 88,640, of which proton pump inhibitors represented the largest proportion (USD 80,350). Medical supplies and prolonged hospitalization were the major contributors to overall expenditures. PUD creates a considerable financial burden on both patients and the healthcare system in Vietnam. Strategies aimed at reducing hospitalization duration and optimizing resource utilization may help decrease treatment costs and improve healthcare efficiency.